title: What else does the JUPITER trial add regarding C-reactive protein and cardiovascular disease?
authors: Gen-Min
authors: GM
authors: Lin
authors: Yi-Hwei
authors: YH
authors: Li
authors: Kai-Min
authors: KM
authors: Chu
authors: Chih-Lu
authors: CL
authors: Han
mesh_terms: D015415:Biomarkers / Q000097:blood; D002097:C-Reactive Protein / Q000378:metabolism*; D002318:Cardiovascular Diseases / Q000453:epidemiology / Q000276:immunology* / Q000378:metabolism*; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data*; D005464:Fluorobenzenes / Q000627:therapeutic use; D006801:Humans; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000627:therapeutic use; D011743:Pyrimidines / Q000627:therapeutic use; D012307:Risk Factors; D000068718:Rosuvastatin Calcium; D013449:Sulfonamides / Q000627:therapeutic use
chemical_list: D015415:Biomarkers; D005464:Fluorobenzenes; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D011743:Pyrimidines; D013449:Sulfonamides; D000068718:Rosuvastatin Calcium; D002097:C-Reactive Protein